Connor, Clark & Lunn Investment Management (CC&L)’s Clovis Oncology, Inc. CLVS Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-65,082	Closed	-$290K	–	1249
2021 Q3	$290K	Buy	+65,082	New	+$313K	﹤0.01%	879
2016 Q3	–	Sell	-10,650	Closed	-$146K	–	933
2016 Q2	$146K	Sell	10,650 -58,025	-84%	-$848K	﹤0.01%	775
2016 Q1	$1.32M	Buy	68,675 +35,175	+105%	+$744K	0.01%	408
2015 Q4	$1.17M	Buy	+33,500	New	+$2.16M	0.01%	424
2013 Q4	–	Sell	-4,300	Closed	-$269K	–	771
2013 Q3	$269K	Buy	4,300 +700	+19%	+$49.6K	﹤0.01%	433
2013 Q2	$254K	Buy	+3,600	New	+$162K	﹤0.01%	447

Other funds holding CLVS

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s CLVS Position: Q4 2021 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Clovis Oncology, Inc. (CLVS) in Q4 2021, closing a stake of 65,082 shares — an estimated $290K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in CLVS in Q2 2013 and held it in 6 quarters. The position peaked at $1.32M in Q1 2016. 153 funds tracked by Wall St. Rank hold CLVS as of Q4 2021.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Clovis Oncology, Inc. position as of Q4 2021 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 65,082 Clovis Oncology, Inc. shares in Q4 2021, an estimated $290K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 6 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Clovis Oncology, Inc. position peaked at $1.32M in Q1 2016.
153 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2021.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2021, filed 10 Feb 2022.